UCB SA (OTCMKTS:UCBJY) Short Interest Down 95.9% in October

UCB SA (OTCMKTS:UCBJY) was the target of a significant drop in short interest in the month of October. As of October 31st, there was short interest totalling 3,000 shares, a drop of 95.9% from the October 15th total of 73,100 shares. Based on an average daily volume of 47,400 shares, the days-to-cover ratio is presently 0.1 days.

UCB Stock Performance

Shares of OTCMKTS UCBJY traded down $1.68 during midday trading on Wednesday, hitting $96.57. The company’s stock had a trading volume of 6,779 shares, compared to its average volume of 16,052. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. UCB has a 1 year low of $34.85 and a 1 year high of $99.40. The business’s fifty day simple moving average is $93.10 and its two-hundred day simple moving average is $82.17.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.